HEALTH OF WOMAN. 2016.1(107):192–196 
 

Gene polymorphisms of biotransformation of xenobiotics and a gene of multiple drug resistance in women with infertility and liver disease 
 

Zhdanovich A. I., Kolomiichenko T. V., Boichuk A. G.

State Institute «Institute of Pediatrics, Obstetrics and Gynecology, NAMS of Ukraine», Kiev

National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev 
 

The aim of the study: to investigate the polymorphic variants of genes of biotransformation of xenobiotics and multidrug resistance gene in women with infertility and disorders of the hepatobiliary system. 
 

Materials and methods. Studied 18 women with infertility: 8 women with functional disorders of the hepatobiliary system, 10 women without such disorders. A molecular genetic study of polymorphic gene variants of multi-drug resistance MDR1 (C3435T), the genes cytochrome P450 isoenzymes Cyp2C19*2 (G681A), Cyp2D6*4 (G1846A) gene family and glutathione-S-transferase (GSTT1, GSTM1, GSTP1). 
 

Results. Found an increase in the frequency of adverse variants of gene polymorphisms of biotransformation of xenobiotics (I phase – cytochrome P450 isoenzymes Cyp2C19*2 and Cyp2D6 *4, II phase – the family of glutathione-S-transferases GSTT1, GSTM1, GSTP1) and multidrug resistance gene MDR1 in women with infertility and functional disorders of the hepatobiliary system, indicating the potential violation bioavailability, drug toxicity or inefficiency recommended dosages of complications therapy, weakening protect cells from the damaging effect of metabolites and free radicals, autointoxication, that collectively lead to the development of various pathological states, particularly during pregnancy, affect the complication of ART programs, their effectiveness and obstetric and perinatal outcomes. 
 

Conclusion. Evaluation of genotype women will identify the potential risks of the use of ART programs in a timely manner to carry out the necessary training, prevention and correction of the relevant irregularities. 
 

Key words: infertility, hepatobiliary disorders, genes biotransformation of xenobiotics, multidrug resistance gene, gene polymorphism. 
 

REFERENCES

1. Ignatova TM. 2008. Lekarstvennye porazheniya pecheni. Gepatologicheskii Forum 2:2–9.

2. Bleibel W, Kim S, D’Silva K, Lemmer ER. 2007. Drug–induced liver injury: rewiew article. Dig Dis Sci. 52:2463–2471. http://dx.doi.org/10.1007/s10620-006-9472-y; PMid:17805971

3. Andreeva MV. 1999. Prognozirovanie narushenii reproduktivnogo zdorov'ya zhenshchin, prozhivayushchikh v razlichnykh ekologicheskikh usloviyakh. Meditsina truda i prom. ekologiya 3:19–21.

4. Nebert DW, Russell DW. 2002. Clinical importance of the cytochromes P450. Lancet. 360:1155–1162 http://dx.doi.org/10.1016/S0140-6736(02)11203-7

5. Woolf TF. 1999. Handbook of drug metabolism:612.

6. Levkovich NM, Gorovenko NG. 2012. Polimorfizm alelnogo variantu *2 gena CYP2C19 u naselennya Ukraini. Perspektivi meditsini ta biologii. 4(2):147–152.

7. Zhou SF. 2009. Polymorphism of human Cytochrome P450 2D6 and its clinical significance: Part I. Clin. Pharmacogenet 48(11):689–723. http://dx.doi.org/10.2165/11318030-000000000-00000; http://dx.doi.org/10.2165/11318070-000000000-00000

8. Sistonen J, Sajantila A, Lao O et al. 2007. 8CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 7(2):93–101.

9. Zanger UM, Raimundo S, Eichelbaum M. 2004. Cytochrome P450 2D6: overviewand update on pharmacology, genetics, biochemistry. Naunin–Schmiedeberg’s Arch. Pharmacol. 369:23–37. http://dx.doi.org/10.1007/s00210-003-0832-2; PMid:14618296

10. Hayes JD, Flanagan JU, Jowsey IR at al. 2005. Glutathione transferases. Annu Rev Pharmacol Toxicol. 45:51–88. http://dx.doi.org/10.1146/annurev.pharmtox.45.120403.095857; PMid:15822171

11. Hayes JD, Strange RC. 2000. Glutathione S–transferase polymorphisms and their biological consequences. Pharmacology 61:154–166. http://dx.doi.org/10.1159/000028396

12. Bespalova ON, Tarasenko OA, Malysheva OV i dr. 2006. Platsentarnaya nedostatochnost' i polimorfizm genov glutation–S–transferaz M1, T1 i R1. Zh. akush. i zhen. Bolezn 55(2):25–31.

13. Garte S, Gaspari L, Alexandrie A et al. 2001. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiology Biomarkers Prevention 10:1239–1248. PMid:11751440

14. MacFarland A, Abramovich DR, Ewen SW, Pearson CK. 1994. Stage–specific distribution of P–glycoprotein in first–trimester and full–term human placenta. Histochem J. 26(5):417–423. http://dx.doi.org/10.1007/BF00160054; PMid:7913921

15. Sun M, Kingdom J, Baczyk D et al. 2006. Expression of the multidrug resistance P–glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta. 27(6–7):602–609. http://dx.doi.org/10.1016/j.placenta.2005.05.007; PMid:16143395